Retinoids, natural and synthetic derivatives of vitamin A, are biological regulators of differentiation, proliferation, apoptosis, and immune response. Retinoic‐acid‐receptor‐selective retinoids (all‐trans retinoic acid, 13‐cis‐retinoic acid, and the synthetic analogs isotretinoin, etretinate and acitretin) have been used for years as monotherapy and/or in combination for treatment of cutaneous T‐cell lymphoma (CTCL). Orally administered bexarotene, the first synthetic highly selective retinoid‐X‐receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL. The topical gel formulation was also effective for early cutaneous manifestations of CTCL or as an adjunct to systemic or phototherapy. Bexarotene treatment induces apoptosis of CTCL cells with down‐regulation of its receptors and of survivin, an inhibitor of apoptosis. Identification of new receptor subtype‐selective retinoids, combination of various receptor‐selective retinoids or other agents, and a new drug delivery system may improve the clinical efficacy of retinoids in the future.